Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma

Of 757 rituximab documents, RCTs of comparisons and outcomes represented <3% of original research. In contrast, review articles, guidelines, editorials, and media reports each outnumbered the relevant original research. The SeBriNA review facilitated the analysis, contextualization, and interpretation of these complex relationships.